Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...

Analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of REGENXBIO in a research report issued to ...

Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta Therapeutics (NASDAQ:SRPT) disclosed a mortality linked to its gene therapy product ...

Regenxbio reports promising microdystrophin expression data in DMD patients, with highest levels in 3-year-old. Plans FDA ...

Regenxbio shares were 13% higher at $8.79, after the company said it saw positive interim data from two new patients in a Phase I/II trial of RGX-202, a differentiated investigational gene therapy for ...

Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 16.3% in the 4th ...

5 analysts have shared their evaluations of Regenxbio (NASDAQ:RGNX) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...

US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated ...